Abstract: The invention relates to a method for determining whether a subject diagnosed with a cardiovascular disease should be prescribed a remote patient management, the method comprising measuring particular biomarkers in a sample from said patient. The invention therefore relates to a method for therapy guidance, stratification and/or monitoring of a remote patient management for a patient diagnosed with a cardiovascular disease, comprising providing at least one sample of a patient, determining a level of at least one biomarker selected from the group consisting of proADM, proBNP and proANP or fragment(s) and comparing said level of the at least one biomarker to one or more reference values, wherein said level is indicative of prescribing or not prescribing a remote patient management for said patient.

Abstract: The use of fibroblast growth factor Fgf7 and of the corresponding receptor Fgfr2b as biomarker candidates for the progesterone receptor antagonist 11?-(4-acetylphenyl)-17B-hydroxy-17?-(1,1,2,2,2-pentafluoroethyl)estra-4,9-dien-3-one, also known under the designations ZK230211 or ZK-PRA, of the formula and for antiestrogens is described.